Literature DB >> 20625319

Effects of individual risk factors on the residual risk of cardiovascular events in a population of treated Chinese patients with hypertension: data from the Felodipine Event Reduction (FEVER) study.

Yuquing Zhang1, Xuezhong Zhang, Lisheng Liu, Alberto Zanchetti.   

Abstract

BACKGROUND AND OBJECTIVES: The added cardiovascular risk conferred by risk factors or diseases accompanying hypertension has been investigated in Caucasian patients, and much less is known in Chinese patients. Furthermore, the residual risk persisting in hypertensive patients, despite blood pressure (BP) reduction, due to accompanying conditions has never been explored in Chinese, and whether they differ from Caucasians under this respect is unknown.
METHODS: Felodipine Event Reduction (FEVER) study randomized 9711 Chinese hypertensive patients to more or less intense antihypertensive treatment for 40 months, with outcome monitoring. The present analyses provide information on the role that baseline presence of individual risk factors has in increasing outcome probability despite BP control. Risk ratios were calculated using Cox proportional hazard models, adjusted for a large number of baseline variables, except the one under examination, and also adjusted for on-treatment systolic and diastolic BP.
RESULTS: Male sex, older age, diabetes and cardiovascular disease were accompanied by a significantly higher incidence of cardiovascular events (risk ratios 1.41-1.86 according to risk factor), stroke (risk ratios 1.42-1.72), cardiac events (risk ratios 1.40-2.70), all-cause death (risk ratios 1.51-2.16) and cardiovascular death (risk ratios 1.61-2.02). Higher baseline systolic BP and smoking conferred a significantly increased risk of cardiovascular events and strokes. Higher cholesterol was not found to increase any cardiovascular outcome. The same was the case for electrocardiographic left-ventricular hypertrophy and isolated systolic hypertension.
CONCLUSIONS: A number of additional risk factors increased the residual risk of Chinese hypertensive patients despite effective antihypertensive treatment as much as described in Caucasians. High serum cholesterol was an exception: whether this is a Chinese characteristic or a more general phenomenon remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20625319     DOI: 10.1097/HJH.0b013e32833cd338

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

Review 1.  New Hypertension Guidelines: Progression or a Step Backwards in Hypertension?

Authors:  Markus van der Giet; Markus Tölle
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

2.  Exploring New Options for Cardiovascular Disease Prevention May Improve Patients' Quality of Life and Outcomes.

Authors:  Giuliano Tocci; Roberto Pontremoli
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-05-09

3.  What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia?

Authors:  Ji-Guang Wang; Yook-Chin Chia; Chen-Huan Chen; Sungha Park; Satoshi Hoshide; Naoko Tomitani; Tomoyuki Kabutoya; Jinho Shin; Yuda Turana; Arieska Ann Soenarta; Jam Chin Tay; Peera Buranakitjaroen; Jennifer Nailes; Huynh Van Minh; Saulat Siddique; Jorge Sison; Guru Prasad Sogunuru; Apichard Sukonthasarn; Boon Wee Teo; Narsingh Verma; Yu-Qing Zhang; Tzung-Dau Wang; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-19       Impact factor: 3.738

4.  Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial.

Authors:  Yu Wang; Zhen Hua; Wenjing Chen; Yushuo Zhu; Yunlun Li
Journal:  Trials       Date:  2022-02-22       Impact factor: 2.279

5.  Effect Modification by Age on the Benefit or Harm of Antihypertensive Treatment for Elderly Hypertensives: A Systematic Review and Meta-analysis.

Authors:  Chi-Jung Huang; Chern-En Chiang; Bryan Williams; Kazuomi Kario; Shih-Hsien Sung; Chen-Huan Chen; Tzung-Dau Wang; Hao-Min Cheng
Journal:  Am J Hypertens       Date:  2019-01-15       Impact factor: 2.689

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.